J. Erik Fyrwald
J. Erik Fyrwald's purchase track record
J. Erik Fyrwald has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2025 | LLY | $1.01M | +54.9% | +60.9% | +7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IFF to Report Q3 2026 Results on November 3. International Flavors & Fragrances is scheduled to release its third-quarter 2026 earnings on November 3, 2026. This upcoming report is the primary driver of recent attention for the stock. The company's shares have been trading near the upper end of their 52-week range, with an RSI of 75.3 suggesting strong recent momentum ahead of the announcement.
Transaction History
| LLY | ▲ Buy | Grant | 9 | $10K | 9/21/2026 | View on chart |
| LLY | ▲ Buy | Grant | 8 | $10K | 8/17/2026 | View on chart |
| LLY | ▲ Buy | Grant | 9 | $10K | 7/20/2026 | View on chart |
| LLY | ▲ Buy | Grant | 9 | $10K | 6/15/2026 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 5/18/2026 | View on chart |
| IFF | ▲ Buy | Option Exercise | 15,875 | $0 | 5/1/2026 | View on chart |
| IFF | ▼ Sell | Tax Withholding | 7,763 | $550K | 5/1/2026 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 4/20/2026 | View on chart |
| IFF | ▲ Buy | Option Exercise | 18,769 | $0 | 4/1/2026 | View on chart |
| IFF | ▼ Sell | Tax Withholding | 8,835 | $641K | 4/1/2026 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 3/16/2026 | View on chart |
| IFF | ▲ Buy | Open Market | 13,360 | $933K | 3/13/2026 | View on chart |
| IFF | ▲ Buy | Open Market | 900 | $62K | 3/12/2026 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 2/17/2026 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 1/20/2026 | View on chart |
| LLY | ▲ Buy | Grant | 9 | $10K | 12/15/2025 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 11/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 215 | $220K | 11/17/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 10/20/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 9/15/2025 | View on chart |
| LLY | ▲ Buy | Grant | 14 | $10K | 8/18/2025 | View on chart |
| LLY | ▲ Buy | Open Market | 686 | $440K | 8/12/2025 | View on chart |
| LLY | ▲ Buy | Open Market | 879 | $565K | 8/12/2025 | View on chart |
| IFF | ▲ Buy | Open Market | 15,300 | $994K | 8/7/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 7/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 6/16/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 5/19/2025 | View on chart |
| IFF | ▲ Buy | Open Market | 24,300 | $1.8M | 5/9/2025 | View on chart |
| IFF | ▲ Buy | Open Market | 700 | $52K | 5/8/2025 | View on chart |
| IFF | ▲ Buy | Option Exercise | 15,875 | $0 | 5/1/2025 | View on chart |
| IFF | ▼ Sell | Tax Withholding | 8,105 | $631K | 5/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 4/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 3/17/2025 | View on chart |
| IFF | ▲ Buy | Open Market | 25,000 | $2.0M | 3/4/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 2/18/2025 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 1/21/2025 | View on chart |
| LLY | ▲ Buy | Grant | 321 | $233K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 12/18/2023 | View on chart |
| LLY | ▲ Buy | Grant | 335 | $200K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $10K | 10/16/2023 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 9/18/2023 | View on chart |
| LLY | ▲ Buy | Grant | 18 | $10K | 8/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 22 | $10K | 7/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 22 | $10K | 6/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 23 | $10K | 5/15/2023 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 4/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 3/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 2/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 28 | $10K | 1/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 28 | $10K | 12/19/2022 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 498 | $180K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 10/17/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 9/19/2022 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $10K | 8/15/2022 | View on chart |
| LLY | ▲ Buy | Grant | 31 | $10K | 7/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 6/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 5/16/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 4/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 34 | $10K | 3/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 41 | $10K | 2/22/2022 | View on chart |
| LLY | ▲ Buy | Grant | 40 | $10K | 1/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 677 | $175K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.